4:26 PM
 | 
Aug 28, 2012
 |  BC Extra  |  Company News

FDA panel backs Humira for UC

FDA's Gastrointestinal Drugs Advisory Committee voted 15-2 that the benefits of Humira adalimumab from Abbott Laboratories (NYSE:ABT) outweigh the potential risks in patients with moderately to severely active ulcerative colitis. While panel members were disappointed by Humira's magnitude of benefit, they felt the mAb against TNF alpha could benefit patients who don't...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >